EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Safety and Efficacy of Non‐Steroidal Topical Aryl Hydrocarbon Receptor Agonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

Martin Cevallos-Cueva iD, Carlos Alberto Monteiro Leitão Neto iD, Devanie Martani iD, Laura Ghanem iD, Camila Almeida Sardinha iD, Daniela Lucía Mendoza-Millán iD, Cristina Sicorschi Gutu iD, Victor Barreiros Pungirum iD, Peter Chien iD

Australasian Journal of Dermatology · 2025

DOI: 10.1111/ajd.14485 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Australasian Journal of Dermatology, 2025. Verfasst von Martin Cevallos-Cueva und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Universidad Central del Ecuador, Quito, Ecuador. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Receptors, Aryl Hydrocarbon, Resorcinols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current first‐line topical treatments for atopic dermatitis (AD) are often limited by concerns related to age, systemic absorption, especially when applied to large body surface areas or under maximal usage conditions and undesirable adverse events (AEs), highlighting the need for alternative therapies.

Methods

We performed a systematic review and meta‐analysis of seven randomised controlled trials (RCT) comparing topical aryl hydrocarbon receptor agonists (TAHRA), including tapinarof and benvitimod cream, to vehicle at different concentrations and application frequencies in patients with AD, which evaluated outcomes such as Investigator Global Assessment (IGA) scores/Validated Investigator's Global Assessment (vIGA), the Eczema Area and Severity Index (EASI‐75), change from baseline in body surface area (BSA) and pruritus score (PS) and safety profiles.

Results

A total of 1631 patients, 1086 received TAHRA, while 545 received vehicle. Overall, TAHRA led to a significant improvement in the IGA/vIGA scores (RR 2.38; 95% CI 1.68 to 3.37; p < 0.00001), EASI‐75 (RR 2.94; 95% CI 2.07 to 4.17; p < 0.00001). Similar findings were observed for mean change from baseline in BSA% (MD −6.08; 95% CI −8.00 to −4.16; p < 0.00001), and PS (Std MD −0.90; 95% CI −1.41 to −0.39; p = 0.0006). The incidence of AEs was significantly higher in the TAHRA group (RR 1.48; 95% CI 1.19 to 1.85; p = 0.0005). We found no significant difference in the incidence of serious adverse events (SAEs) (RR 1.51; 95% CI 0.34 to 6.64; p = 0.59). Treatment‐emergent adverse events (TEAEs), such as folliculitis, were more frequent in the TAHRA group (RR 8.06; 95% CI 2.75 to 23.60; p = 0.0001).

Conclusion

Our findings support the efficacy of TAHRA among different metrics with minimal and tolerable AEs and its use as a valuable new non‐steroidal option for the treatment of AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicReceptors, Aryl HydrocarbonResorcinolsHumansRandomized Controlled Trials as TopicStilbenes

Stichwörter der Autor:innen

TAHRAatopic dermatitisbenvitimodtapinaroftopical aryl hydrocarbon receptor agonists

Substanzen

Receptors, Aryl HydrocarbonResorcinolstapinarofStilbenes

Autor:innen und Institutionen

  • School of Medicine, Universidad Central del Ecuador, Quito, Ecuador.
  • Faculty of Medicine, University of Pavia, Pavia, Italy.
  • Faculty of Medicine, Universitas Tarumanagara Jakarta, Jakarta, Indonesia.
  • Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
  • Faculty of Medical Sciences, Faculty of Minas, FAMINAS- BH, Belo Horizonte, Brazil.
  • Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

ORCID-Profile: Martin Cevallos-Cueva, Carlos Alberto Monteiro Leitão Neto, Devanie Martani, Laura Ghanem, Camila Almeida Sardinha, Daniela Lucía Mendoza-Millán, Cristina Sicorschi Gutu, Victor Barreiros Pungirum, Peter Chien

Zitieren

APA

Cevallos-Cueva, M., Neto, C. A. M. L., Martani, D., Ghanem, L., Sardinha, C. A., Mendoza-Millán, D. L., Gutu, C. S., Pungirum, V. B., & Chien, P. (2025). Safety and Efficacy of Non‐Steroidal Topical Aryl Hydrocarbon Receptor Agonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14485

Vancouver

Cevallos-Cueva M, Neto CAML, Martani D, Ghanem L, Sardinha CA, Mendoza-Millán DL, et al. Safety and Efficacy of Non‐Steroidal Topical Aryl Hydrocarbon Receptor Agonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials. Australasian Journal of Dermatology. 2025. doi:10.1111/ajd.14485

BibTeX
@article{CevallosCueva2025,
  author = {Cevallos-Cueva, Martin and Neto, Carlos Alberto Monteiro Leitão and Martani, Devanie and Ghanem, Laura and Sardinha, Camila Almeida and Mendoza-Millán, Daniela Lucía and Gutu, Cristina Sicorschi and Pungirum, Victor Barreiros and Chien, Peter},
  title = {Safety and Efficacy of Non‐Steroidal Topical Aryl Hydrocarbon Receptor Agonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials},
  journal = {Australasian Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ajd.14485}
}
Kostenlos starten →